- Challenge from new variants will necessitate periodic updates to COVID-19 vaccines, with first boosters likely needed in late 2021
- Countries with advanced mass vaccination rollouts will remain likely to exit pandemic phase in second half of this year
- Wider global progress out of pandemic will be more uneven and protracted, potentially for some outliers until 2023
Novavax released data on 28 January for its two-dose protein-based vaccine candidate, following trials involving 15,000 participants in the UK and over 4,400 in South Africa.
Falanx Assynt is a global intelligence consultancy and leading provider of geopolitical, strategic and business risk analysis since 2003. Falanx Assynt is part of Falanx Group Ltd (LON:FLX) which, through its subsidiaries, provides cyber defence and intelligence services to blue chip and government clients worldwide.